- Home
- ANNX vs SGC Comparison
ANNX vs SGC Comparison
Compare ANNX & SGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- SGC
- Stock Information
- Founded
- ANNX 2011
- SGC 1920
- Country
- ANNX United States
- SGC United States
- Employees
- ANNX N/A
- SGC N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- SGC Apparel
- Sector
- ANNX Health Care
- SGC Consumer Discretionary
- Exchange
- ANNX Nasdaq
- SGC Nasdaq
- Market Cap
- ANNX 253.8M
- SGC 215.7M
- IPO Year
- ANNX 2020
- SGC N/A
- Fundamental
- Price
- ANNX $2.06
- SGC $13.14
- Analyst Decision
- ANNX Strong Buy
- SGC Strong Buy
- Analyst Count
- ANNX 5
- SGC 3
- Target Price
- ANNX $13.00
- SGC $17.33
- AVG Volume (30 Days)
- ANNX 1.2M
- SGC 45.9K
- Earning Date
- ANNX 08-14-2025
- SGC 08-05-2025
- Dividend Yield
- ANNX N/A
- SGC 4.26%
- EPS Growth
- ANNX N/A
- SGC N/A
- EPS
- ANNX N/A
- SGC 0.52
- Revenue
- ANNX N/A
- SGC $576,240,000.00
- Revenue This Year
- ANNX N/A
- SGC $1.46
- Revenue Next Year
- ANNX N/A
- SGC $3.32
- P/E Ratio
- ANNX N/A
- SGC $25.18
- Revenue Growth
- ANNX N/A
- SGC 4.03
- 52 Week Low
- ANNX $1.29
- SGC $9.11
- 52 Week High
- ANNX $7.85
- SGC $18.48
- Technical
- Relative Strength Index (RSI)
- ANNX 38.44
- SGC 63.12
- Support Level
- ANNX $2.06
- SGC $12.76
- Resistance Level
- ANNX $2.36
- SGC $13.78
- Average True Range (ATR)
- ANNX 0.17
- SGC 0.59
- MACD
- ANNX -0.03
- SGC 0.09
- Stochastic Oscillator
- ANNX 1.52
- SGC 70.23
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.